A Study to Evaluate the Pharmacokinetics, Safety and Tolerability, Immunogenicity, and Pharmacodynamics of GSK2800528 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 17 May 2017
Price : $35 *
At a glance
- Drugs GSK 2800528 (Primary) ; Adalimumab
- Indications Psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 01 May 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.